TDCS for Cocaine Addiction Craving

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-01

Study Completion Date

2019-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which low level electrical currents are applied to the scalp in order to alter brain function. In the present study, tDCS will be administered with the goal of assessing the tolerability and feasibility of this approach to 1) reduce an individual's level of drug craving and 2) provide evidence to support the use of this device by the patient for future unsupervised stimulation in a non-clinical setting.

Research Questions:

* Can tDCS be used successfully to train cocaine addicted individuals for self-administration purposes?
* Can active tDCS be used to decrease drug craving in individuals with cocaine use disorders?
* Does active tDCS outperform sham tDCS in reducing drug craving?

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study

NCT04994821

Cocaine Use Disorder Cocaine Dependence

COMPLETED PHASE2

Transcranial Direct Current Stimulation (tDCS) for Treatment of Cocaine Use Disorder

NCT07318480

Cocaine Use Disorder Cocaine Dependence Substance Use Disorder (SUD)

RECRUITING NA

Effects of tDCS on Craving, Relapse and Cognitive Functions Among Patients With Cocaine Use Disorder

NCT03025321

Cocaine Addiction

COMPLETED NA

Prefrontal Cortex Stimulation as Treatment for Crack-cocaine Addiction

NCT01337297

Cocaine Addiction Cocaine-related Disorder Executive Dysfunction

COMPLETED PHASE1/PHASE2

Transcranial Magnetic Stimulation for Cocaine Addiction

NCT03333460

Cocaine Dependence Substance Use Disorders Chemical Addiction +3 more

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ultimate goal of this project is to develop a portable neuromodulatory intervention to reduce craving in cocaine addiction. This proposed project is in response to NIH/NIDA's solicitation titled "Development of Portable Neuromodulatory Device for the Treatment of Substance Use Disorders (SUDs)." The present study aims to evaluate the tolerability and feasibility of repeated administration of tDCS to reduce drug craving in individuals with cocaine addiction, with the aim of using these data to support a phase II study and, ultimately, support of approval of usage of this device without clinical supervision.

The specific objectives are:

1. Establish the feasibility and safety of using tDCS to reduce self-reported cravings in individuals addicted to cocaine.
2. Train cocaine addicted individuals to self-administer tDCS (under supervision) to test the feasibility of future home self-administration in this population.

Substance use disorders present a treatment challenge for clinicians, as well as a socioeconomic burden on individuals and society at large. Cocaine use disorder occurs when someone experiences clinically significant impairment caused by the recurrent use of cocaine, including health problems, physical withdrawal with discontinuation of use, persistent/escalating use, and failure to meet major personal, occupational, or educational responsibilities. At present, no FDA approved medicines are available to treat cocaine dependence, and behavioral therapy may be used to treat this addiction, though with limited efficacy. Drug craving (strong obsessions about and/or irresistible urges or compulsions to consume a drug) is a central driving force for perpetuation of substance use and subsequent addiction, as well as relapse after abstinence. Currently, no treatments exist that are targeted at reducing drug craving, which is intrusive and distressing to patients. The prefrontal cortex (PFC) plays an important role inhibiting these intrusive cravings. However, decades of data have shown that PFC activity is impaired in addictions. In this study, our goal is to increase PFC activity with non-invasive neuromodulation. Given the role of the PFC in the processing and regulation of craving behavior, this brain region is a key target for brain stimulation.

This study will recruit individuals with a diagnosis of cocaine use disorder (per DSM-5 criteria) who are receiving treatment for their substance use disorder at Samaritan Daytop Village (SDV) and other similar treatment facilities (e.g., Phoenix House, Mount Sinai's network of hospitals and clinics). Patients will be randomly assigned to receive either active or sham (placebo) tDCS. Participants will receive 20 minutes of stimulation per tDCS day, three days per week for five weeks.

Interviews and neuropsychological testing will be conducted, and self-reported drug craving and addiction severity questionnaires will be used. Follow up cognitive and behavioral assessments will be conducted over a period of 12 months post tDCS stimulation. In addition, participants will be asked to perform EEG, cognitive tasks, and collection of a blood sample to assess genetic/epigenetic patterns.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cocaine Use Disorder Cocaine Dependence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DEVICE_FEASIBILITY

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active tDCS

Active Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator

Group Type EXPERIMENTAL

Soterix Medical mini-CT tDCS stimulator

Intervention Type DEVICE

Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.

Stimulation will last 20 minutes per day, three days per week, for 5 weeks

Sham tDCS

Sham (Placebo) Transcranial Direct Current Stimulation (tDCS), Soterix Medical mini-CT tDCS stimulator

Group Type SHAM_COMPARATOR

Soterix Medical mini-CT tDCS stimulator

Intervention Type DEVICE

Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.

Stimulation will last 20 minutes per day, three days per week, for 5 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Soterix Medical mini-CT tDCS stimulator

Patients will have two electrodes applied (one anode, one cathode) administering active (real) or sham (placebo, not real) tDCS stimulation.

Stimulation will last 20 minutes per day, three days per week, for 5 weeks

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* DSM-5 diagnosis of cocaine use disorder
* Ability to understand the risks/benefits of the study, provide informed consent and perform tasks as per protocol
* English speaking
* For females of childbearing capacity, current use of a medically acceptable form of birth control

Exclusion Criteria

* Current or past history of a major neurological disorder (e.g. mental retardation, Parkinson's disease, Lewy body disease, Huntington's disease, MS, ALS, stroke, delirium tremens) or seizures, including those symptoms associated with periods of cocaine withdrawal or abstinence
* History of Axis I disorder, other than substance use disorder, that is associated with psychotic symptoms (e.g. schizophrenia) or neurodevelopmental disorder (e.g., autism)
* Use of medications (current or in the past 6 months) with known CNS effects or which may alter cerebral function, except psychotropics for depression/anxiety/PTSD (e.g. SSRIs)
* Clinically significant unstable medical illness or infection (e.g. HIV, hepatitis, etc.)
* Presence of contraindicated metallic implants or devices which may be impacted by electrical stimulation (e.g. cardiac pacemaker/defibrillator, medication pump, cochlear implant, implanted brain stimulator)
* Head trauma with loss of consciousness for more than 30 minutes
* Pregnancy or breast feeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No